Email updates

Keep up to date with the latest news and content from DARU Journal of Pharmaceutical Sciences and BioMed Central.

Open Access Review article

Cost effectiveness of Iran national plasma contract fractionation program

Abdol Majid Cheraghali

Author Affiliations

High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and Faculty of Medicine, University of Baqiyatallah Medical Sciences, Tehran, Iran

DARU Journal of Pharmaceutical Sciences 2012, 20:63  doi:10.1186/2008-2231-20-63

Published: 22 October 2012

Abstract

Plasma derived medicines (PDM) including immunoglobulins, clotting factors and albumin are life saving medicines which due to their high costs are inaccessible for many patients living in developing countries. By contrary substantial volume of plasma as raw materials for production of these medicines are discarded worldwide. Good quality recovered plasma, as a result of separation of donated blood into its components, could be used for production of PDM. In 2011 Iranian donors donated about 2 million units of blood. A shift from administration of whole blood to components therapy has resulted in the generation of over 250,000 liters of surplus of recovered plasma. This created a good opportunity for Iran’s health care system to use this plasma for production of PDM. Therefore Iran national transfusion service has started a contract fractionation program for converting recovered plasma into PDM. This program not only provided essential PDM for Iran pharmaceutical market but also has created a direct saving of about 8.5 million Euros in 2011 for national health sector. In addition this program has drastically contributed to improvement of overall quality of working procedures and services provided by Iran national blood transfusion organization.

Keywords:
Iran; Cost effectiveness; Plasma contract fractionation; Blood transfusion service